The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 10, 2018

Filed:

Dec. 20, 2013
Applicants:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Alectos Therapeutics, Inc., Burnaby, CA;

Inventors:

Harold G. Selnick, Ambler, PA (US);

Kun Liu, Needham, MA (US);

Ernest J. McEachern, Burnaby, CA;

Ramesh Kaul, Burnaby, CA;

Zhongyong Wei, Beijing, CN;

Yaode Wang, Beijing, CN;

Jiang Chang, Beijing, CN;

Assignees:

ALECTOS THERAPEUTICS, INC., Burnaby, British Colombia, CA;

MERCK SHARP & DOHME CORP., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07D 513/04 (2006.01); B65D 71/14 (2006.01); B65D 71/16 (2006.01); B65D 5/00 (2006.01); B65D 5/20 (2006.01);
U.S. Cl.
CPC ...
C07D 513/04 (2013.01); B65D 5/005 (2013.01); B65D 5/2057 (2013.01); B65D 71/14 (2013.01); B65D 71/16 (2013.01); B65D 2571/0016 (2013.01); B65D 2571/0029 (2013.01); B65D 2571/0066 (2013.01); B65D 2571/00716 (2013.01);
Abstract

The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.


Find Patent Forward Citations

Loading…